Purpose
Obesity, obesity, overweight, NAFLD
OBESITY, OBESITY, NONALCOHOLIC FATTY LIVER DISEASE, CHRONIC DISEASES, TYPE 2 DIABETES, DISEASES
Edited by: Alexandre Gabarra Oliveira, São Paulo State University, BrazilReviewed by: Aisha Musaazi Sebunya Nakitto, Victoria University, Uganda; Zahra Abedi Kichi, LMU Munich University Hospital, Germany; Giovanni Tarantino, University of Naples Federico II, Italy†These authors have contributed equally to this workThis article was submitted to Obesity, a section of the journal Frontiers in EndocrinologyIt is known that obesity has a multifactorial etiology that involves genetic and environmental factors. The WHO estimates the worldwide prevalence of 1.9 billion overweight adults and more than 650 million people with obesity. These alarming data highlight the high and growing prevalence of obesity and represent a risk factor for the development and aggravation of other chronic diseases, such as nonalcoholic fatty liver disease (NAFLD) that is frequently considered the hepatic outcome of type 2 diabetes. The use of non-pharmacological therapies such as food supplements, nutraceuticals, and natural integrative therapies has grown as an alternative tool for obesity-related diseases compared to conventional medications. However, it is a still little explored research field and lacks scientific evidence of therapeutic effectiveness. Considering this, the aim is to evaluate whether a new nutraceutical supplement composition can improve and supply essential mineral nutrients, providing an improvement of obesity-related metabolic and endocrine parameters.